bevacizumab,atezolizumab,cisplatin,pembrolizumab
roche,merck
['atezo', ' bev ', 'imbrave050', 'gi ', 'hcc']
my takeaway from #asco23 gi day 1: 1. imbrave050: adjuvant atezo + bev for high risk hcc after resection/rfa had sig improved rfs compared w/ surveillance similar hrqol curves crossed at 24 mos awaits os data. potentially practice changing, pending long term f/u 
Incoming GI oncologist at UW Fred Hutch Cancer Center. Graduating UPMC fellow. Trials/early phase/AI/ML. Views my own. ✈️🚵‍♀️🏔🏸⚾️🎥.